Novartis US Foundation & Corporate Responsibility

YYLYY YYYYYYYYYYY



UNOVARTIS

Reimagining Medicine

Advancing health equity by amplifying and embedding minority patient voices throughout research, development and healthcare

BEACON of **HOPE** - co-creating solutions to address the root causes of health inequity in US over 10 years

Patrice Matchaba, MD

Head Novartis US Corporate Responsibility & President Novartis US Foundation

MassBIO Conference 21 July 2022


"Of all the forms of inequality, injustice in health care is the most shocking and inhumane."

> Dr. Martin Luther King Jr. March 25, 1966

The COVID-19 Pandemic has highlighted the disproportionate and systemic health impact on communities of color in the US



MARCH 22, 2020 SEAN FREEMAN: CORONAVIRUS



The New York Times

U.S. Life Expectancy Plunged in 2020, Especially for Black and Hispanic Americans

The 18-month drop, the steepest decline since World War II, was fueled by the coronavirus pandemic.

Reimagining Medicine

U NOVARTIS

3 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022

Health disparities in the US based on race are not only unethical but they also cost lives and waste resources

~USD 93bn in excess medical care costs, USD 42bn in lost productivity / year¹

In US, **40%** more black people have died from COVID-19 vs. white people²



NOVARTIS |

1. American Public Health Association. 2. COVID Tracking Project and the Boston University Center for Antiracist Research, https://covidtracking.com/race

Reimagining Medicine

FDA U.S. FOOD & DRUG

CENTER FOR DRUG EVALUATION AND RESEARCH

DRUG TRIALS SNAPSHOTS SUMMARY REPORT 2021



2021 Summary Statistics January 1, 2021 - December 31, 2021

In 2021, CDER approved 50 novel drugs, either as new molecular entities (NMEs) under new drug applications (NDAs) or as new therapeutic biologics under biologics license applications (BLA). The 2021 annual report highlights demographic data from some novel therapeutics approved in the following categories:

- Heart, Blood, Kidney, and Endocrine Diseases
- Autoimmune, Inflammatory, and Lung Diseases
- Infectious Diseases
- Neurological and Psychiatric Disorders
- Cancers
- Other Advances in Drug Therapies

We hope information from this annual report will help promote further dialogue on how drug development can be enhanced to improve knowledge about the safety and effectiveness of therapies across the diverse patient community in the United States.

Heart, Blood, Kidney and Endocrine Diseases

In 2021, ten novel therapies were approved for medical conditions affecting the heart, blood, kidney, or endocrine system (Table 1).

Table 1. Summary of Demographic Data for Novel Therapies Approved to Treat Heart, Blood, Kidney, and Endocrine Diseases (numbers represent percentage of patients studied)

Female ¹	White ²	Black ²	Asian ²	Hispanic ^a	≱ 65 yrs'	Indication	Female ¹	White ²	Black ²	Asian ²	Hispanic	≩ 65 yrs4
39	98	0	0.6	NA	33	To treat short stature due to inadequate	18	94	2	1	4	0
fo mitigate chemother- 33 95 NA NA NA apy-induced myelosup- pression in small cell		47	secretion of endogenous growth hormone*									
		To mitigate the risk of cardiovascular death			24	64	5	22	16	63		
61	61	3	15	NA	21	and hospitalization for chronic heart failure						
54	74	3	15	3	12	To improve growth in chil- dren achondroplasia*	47	71	4	19	6	0
30	63	5	25	15		To treat severe hypogly- cemia – adults	40	92	2	3	8	4
	To treat severe hypogly-	52	94	NA	NA	17	0					
32	92	6	1	6	53	cemia – pediatrics						
	39 33 61 54 30	39 98 33 95 61 61 54 74 30 63	39 98 0 33 95 NA 61 61 3 54 74 3 30 63 5	39 98 0 0.6 33 95 NA NA 61 61 3 15 54 74 3 15 30 63 5 25	39 98 0 0.6 NA 33 95 NA NA NA 61 61 3 15 NA 54 74 3 15 3 30 63 5 25 15	39 98 0 0.6 NA 33 33 95 NA NA NA 47 61 61 3 15 NA 21 54 74 3 15 3 12 30 63 5 25 15 58	39 98 0 0.6 NA 33 33 95 NA NA NA 47 33 95 NA NA A47 61 61 3 15 NA 21 54 74 3 15 3 12 30 63 5 25 15 58 To treat severe hypogly-cemia – adults To treat severe hypogly-cemia – adults To treat severe hypogly-cemia – adults	39 98 0 0.6 NA 33 33 95 NA NA NA 47 61 61 3 15 NA 21 54 74 3 15 3 12 30 63 5 25 15 58 To treat severe hypogly-cemia – adults 52 54 54	399800.6NA333395NANANA473395NANANA476161315NA21547431531230635251558To treat severe hypogly-cemia - adults4092To treat severe hypogly-cemia - adults5294	39 98 0 0.6 NA 33 33 95 NA NA NA 47 33 95 NA NA NA 47 61 61 3 15 NA 21 54 74 3 15 3 12 30 63 5 25 15 58 To treat severe hypogly-cemia – adults 40 92 2 To treat severe hypogly-cemia – adults 52 94 NA	39 98 0 0.6 NA 33 33 95 NA NA NA 47 61 61 3 15 NA 21 54 74 3 15 33 12 30 63 5 25 15 58 To treat severe hypogly- cernia – adults 40 92 2 3	39 98 0 0.6 NA 33 33 95 NA NA NA 47 33 95 NA NA NA 47 61 61 3 15 NA 21 54 74 3 15 3 12 30 63 5 25 15 58 To treat severe hypogly- cemia – adults 40 92 2 3 76 74 74 74 74 74 74 74 74 74

NA - data not available | *Orphan disease | Further explanation of footnotes click here

6 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022


We need to do a better job to increase not only patients and women of color in Clinical Trials but also Trial Investigators – from POC to Phase 3 Trials



Only 5 % of Doctors identified as African American or Black (vs13.4% of population) and less than 2% engaged in Clinical rials

Black and Hispanic workers remain underrepresented in the STEM workforce

% who are...



Reimagining Medicine

Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022

Trust and the past matters - Tuskegee, Henrietta Lacks and J. Marion Sims (the father of gynecology)



Herman Shaw, one of the last survivors of the Tuskegee study, raises his arms with praise as President Bill Clinton apologizes for the infamous experiment. (Susan Biddle/Washington Post)



induced to serve as guinea Doctors in the service s pigs, have gone without medithey are now rendering who eatment for the disease ever other medical service and a few have died of its they can give to the survivor ects, even though an efwhile the study of the disease fective therapy was eventually Dr. Merlin K. DuVal, Assis The study was conducted to ant Secretary of Health, Educe determine from autopsies what the disease does to the human tion and Welfare for Healt and Scientific Affairs, en


Officials of the health serv the study. He said that he wa ice who initiated the experimaking an immediate invest ment have long since retired. gation Current officials, who say they

The experiment, called Tuskegee Study, began i 1932 with about 600 black mer

shock on learning e



Administration on Nav 12, 2017, Photo Credit: Courtesy of the National Archives and Record





Racial bias and sexism are deeply embedded in how we practice medicine and deliver healthcare

Science & technology Apr 10th 2021 edition >

The

Economist

How medicine discriminates against non-white people and women

Race and sex bias in medicine

Many devices and treatments work less well for them





Dr. Susan Moore, in a screenshot from a video she took while hospitalized with Covid-19.



Published Dec. 23, 2020 Updated Dec. 25, 2020

The New York Times

Why this matters – Case example of the negative health impact of using race in assessing kidney function

	DNAL KIDNEY IDATION		Login)
idney Basics	Treatment & Support	Kidney Donation	Kidney Professionals	Research
	Removing Race Kidney Functio		ates of	
	March 9, 2021 - A joint statement from and the National Kidney Foundation	n the presidents of the America	n Society of Nephrology	
	More than 37 million adults in the U	nited States have kidney dise	ases.	
	A disproportionate number of those Latino, American Indian or Alaska N Pacific Islander, who also face unac care delivery.	lative, Asian American, and N	ative Hawalian or Other	

- Overestimation of renal function of African Americans using race and creatinine
- Late to be diagnosed with kidney failure
- Last on list for dialysis
- Last on list for kidney transplants

Race and sex-based data standards that have not been validated costs life's and need to be overhauled urgently.

Reimagining Medicine

NOVARTIS

Why this matters – another case example of lung function test "race correction" built into spirometers



- Spirometers automatically factor in a 10% decrease in lung functions for African Americans as normal
- Therefore, they have to lose more lung capacity before diagnosis made
 - Delay in treatment
 - Less compensation in industrial/occupational exposure

Based on justification of race inferiority during slavery

All Pictures Archive / Alamy Stock Photo

11 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022

Obstetrics



- Vaginal Birth After Cesarean VBAC Risk Calculator
- Race African American Women
 - Bleeding risk increase
 - Anesthesia risk
 - Maternal Mortality

AA Film Archive / Alamy Stock Photo

12 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022



Why this matters – the integration of unvalidated "race correction" into the practice of medicine is deep and extensive



N ENGLJ MED 383;9 NEJM.ORG AUGUST 27, 2020

13 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022

- NEJM Published more than 10 other serious diseases where race is imputed based on no evidence, to the detriment of African Americans
- This has a huge impact on individual patients and population health globally

After 4 months of intense discussion with African American communities and deans of Historically Black Medical Schools we leant that :

- Developing Trust by consulting and co-creating the program with the African American Community
- Address STEM Education and generational wealth gap college fees are prohibitive
- Address HBUCs underfunding and lack of endowments
- Develop Human Capital and knowledge transfer about R&D
- Health Inequity is complex and "a system-based approach is best suited"

It will take time

Health Inequity in the US today is a result of centuries on inequity across every walk of life



14 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022

If you build it they will come




ZUMA Press, Inc. / Alamy Stock Photo



AA Film Archive / Alamy Stock Photo

15 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022

"And they did come"



Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022 16

Reimagining Medicine

A Historic PLEDGE called the Beacon of Hope to address the systemic causes of

Health Inequity impacting African Americans and Hispanics : July 2021

We believe that through concerted action we can deliver measurable impact. Moreover, we hope that through our efforts we can help to enlist others to this cause, including other biotechnology and pharmaceutical companies who share the same vision and objectives. Upon signature of this pledge, as a first step toward our planned 10-year collaboration, our goal is to spend the next 6 months co-creating potential solutions with the communities we aim most to impact, for we are united in our mission to positively bend the curve of life for all.

Valori ARan

MEDIA & INVESTOR RELEA	ASE
------------------------	-----

17

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities. Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

- Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and others to address root causes of disparities in health and education
- This collaboration will create actionable solutions to target the systemic racism that drives inequitable health outcomes and work together for health equity progress through greater diversity, equity and inclusion across the research and development ecosystem
- Novartis US Foundation plans to invest approximately \$13.7 million to establish three digitally enabled research centers at Morehouse School of Medicine. including a clinical trial center of excellence that could be a model for possible

Vas Narasimhan, M.D. Patrice Matchaba MD Chief Executive Officer President Novartis US Rice Novartis Foundation & Head of President Novartis US Corporate Morehouse School Responsibility of Medicine Smr. Du Conte Martin Hamlette .ID Jeff Maggioncalda Dr. James Hildreth MHA CEO President Executive Director Coursera Meharry Medical National Medical College Association TEHA where Sull Vernell Bennith Fries Dr. Wayne Frederick Dr. Thomas K. Hudson Dr. Vernell A. Bennett-President Fairs President Howard University Jackson State President LeMoyne Owen University College Hard 2. matin Art A Morans hill Dr. David A. Thompson Dr. David K. Wilson Dr. Harold Martin President President Chancellor Morehouse University Morgan State North Carolina

University

Debelaco

120-Dr. Valerie Montgomerv Dr. Harry L. Williams President & CEO Thurgood Marshall College Fund

Townall.

Dr. David Carlisle

Charles Drew University

of Medicine and Science

114

President

Pennsylvania

Onth J. Seam

President

University

Dr. Ruth J. Simmons

Prairie View A&M

Dr. Brenda Allen

Lincoln University in

President

Agricultural & Technical State University

President

Nattal Kelin Dr. Walter Kimbrough Dillard University

Dr. Ray Belton

Chancellor/President

Southern University

and A&M College

Charlette & Marino

achen Huge of

Alabama A&M

President

University

Dr. Andrew Hugine

V-N.S.S. Larry Rabinson Dr. Bann Newkirk Dr. Larry Robinson President President Florida A&M University **Fisk University**

ani tother any

Dr. Aminta H. Breaux

Bowie State University

President

2. Cotton Dr. William R. Harvey President Hampton University

In a

President

University

Dr. Tony Allen

Delaware State

by A. Stul

Acres T. Trulla

George French, Jr.

Clark Atlanta University

President

Dr. Glenda Glover President

University

Kenneth Huewitt Interim President Texas Southern University

Joh M Quang

Dr. Charlotte P. Morris Interim President Tuskegee University

Dr. Heidi Anderson President University of Maryland Eastern Shore

Dr. Mary Schmidt

Spelman College

Campbell

President

President

of Louisiana

Shaft then Dr. Reynold Verret Xavier University

Tennessee State

Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022

Johnda Johner the I finit

Beacon of Hope: 10-year faculty support to run Centers of Excellence for Clinical Trials in the Four Historically Black Medicals Schools – starting at Morehouse School of Medicine



Valerie Montgomery Rice, MD, FACOG

Center of Excellence for Clinical Trials

Center of Excellence for Climate, Environment and Health

Center of Excellence to Review the use of "Race Correction in Medicine"

President and CEO, Morehouse School of Medicine

18 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022



Beacon of Hope - addressing generational wealth, STEM and research gaps over 10 years

- <u>1200 Students</u> Novartis Mentoring to prepare them for careers in Industry and Research and Development
- <u>340 Scholarships</u> for students
- 90 HBCU Faculty Research Grants



U NOVARTIS







Harry L. Williams

President and CEO Thurgood Marshall College Fund




TMCF-Novartis US Foundation HBCU Alliance Announce Faculty Grant Winners

\$2.25 million will be granted over 10 years to HBCU faculty at select institutions

June 21, 2022 16:25 ET | Source: Thurgood Marshall College Fund

20 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022







U NOVARTIS |

21 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022

Reimagining Medicine



TMCF – Novartis Foundation Alliance Scholarships winners : first group of <u>120 students</u> to be announced next month



NATIONAL ACADEMIES Sciences Engineering Medicine

This PDF is available at http://nap.naptionalacademies.org/26479

Washington, DC

NATIONAL

PRESS

ACADEMIES



Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups (2022)

DETAILS

440 pages | 6 x 9 | PAPERBACK ISBN 978-0-309-27820-1 | DOI 10.17226/26479

CONTRIBUTORS



Kirsten Bibbins-Domingo and Alex Helman, Editors; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research; Committee on Women in Science, Engineering, and Medicine; Policy and Global Affairs; National Academies of Sciences, Engineering, and Medicine

SUGGESTED CITATION

National Academies of Sciences, Engineering, and Medicine 2022. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington, DC: The National Academies Press. https://doi.org/10.17226/26479. Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this dard document should be submitted within 60 days of publication in the *Fallowil Register* of the noise announcempt the valiability of the dard guidance. Submit electronic comments to <u>impreview mentations nor</u>, Submit written comments to the Dockets Management Starf [174-305]. For dard fall Drug Administration, 560 Fabers Lane, Run. 1061, Rockville, MD 20852. All Comments should be identified with the docket number issued in the noise of availability that publicates in the *Federal Register*.

For questions regarding this draft document, contact (OCE/CDER) Lola Fashovin-Aje, 240-402-0205, (CBER) Office of Communication. Outreach, and Development, 800-835-4709, or 240-402-8010, or CDRHClinicat/enderof/fith lisks gov.

> U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence (OCE) Center for Drug Evaluation and Research (CDER) Center for Bolgiet Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) Offse of Minorite Health Aquity (OMHHE)

> > [Date] Clinical/Medical

June 22, 2022 Expansion of Beacon Of Hope Partnership

Novartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparities

Back to News Archive











Merck, Sanofi join Novartis' 10-year quest to improve clinical trial diversity as historically Black colleges pitch in

Kyle LaHucik

HOWARD UNIVERSITY ARTICLE | PRODUCT DEVELOPMENT

Novartis expands partnership with HBCUs, adds Sanofi and Merck

Beacon of Hope aims to address racial health disparities by increasing diversity among clinical trial participants and investigators

BY KAREN TKACH TUZMAN, SENIOR EDITOR June 22, 2022 9:16 PM EDT









Charles R. Drew University of Medicine and Science





Which diseases your research and develop medicines for also matters and is core to DEI in Science





AA Film Archive / Alamy Stock Photos



KOF

March 13, 1946 - May 7, 2022 Novartis Beacon of Hope | MassBIO DEI Boston Confrence | 21 July 2022

"IT ALWAYS SEEMS IMPOSSIBLE UNTIL IT IS DONE"

NELSON MANDELA

PRISONER #46664



YXXYXXXXX YYYYYY \mathbf{x} LYYLYY LYYYYYY \mathbf{x} \mathbf{x} イメイイイイイイ \mathbf{x} LYYLYI \mathbf{x} イメイイイイイイ YY + YY + Y**YXXXXXXXX** YYYYYYYYY



Thank you